Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system.

ABSTRACT:

Objective

Quetiapine, an atypical second-generation antipsychotic drug, is approved for treatment of schizophrenia, bipolar disorder, and depression. Due to the limitations of clinical trials, the association between quetiapine and rare cardiac adverse events (AEs) is still unclear. This study is to evaluate quetiapine-associated cardiac AEs through data mining of FDA Adverse Event Reporting System (FAERS).

Methods

Reporting odds ratio (ROR) was used to quantify the signals of quetiapine-related cardiac AEs from the first quarter (Q1) of 2018-2022 Q1. Serious and nonserious cases were compared, and signals were prioritized using a rating scale.

Results

A total of 1004 cases of quetiapine-associated cardiac AEs were identified, with 31 signals being detected, among whi

SUBMITTER: Shu Y 

PROVIDER: S-EPMC10401141 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature